The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
Primary Purpose
Type 2 Diabetes, Stroke, Myocardial Infarction
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
glucagon-like-peptide-1
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring GLP-1, glucose metabolism, Type 2 diabetes, brain, PET
Eligibility Criteria
Inclusion Criteria:
- Healthy men
- Age 20-50 years
- Caucasian
- BMI 20-30 kg/m2
Exclusion Criteria:
- Diabetes in subject and 1.degree relatives
- Any disease of clinical relevance
Sites / Locations
- Department of pharmacology, Aarhus university
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
A
P
Arm Description
Outcomes
Primary Outcome Measures
The acute effect of GLP-1 on glucose uptake in the brain
The acute effect of GLP-1 on glucose uptake in the heart
Secondary Outcome Measures
The acute effect of GLP-1 on glucose metabolic rate in the brain
The acute effect of GLP-1 on intracerebral glucose concentration
The acute effect of GLP-1 on lumped constant in the brain
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00418288
Brief Title
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
Official Title
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Subjects During Hypoglycemia Assessed by Positron Emission Tomography
Study Type
Interventional
2. Study Status
Record Verification Date
June 2008
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
February 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Aarhus
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Type 2 diabetes mellitus, T2D is a disease characterized by an immense growing prevalence world wide with an increased risk of myocardial infarction and stroke. GLP-1 has convincing effects on the high glucose levels in type 2 diabetic patients and is well tolerated. New animal studies indicate a protective effect of GLP-1 in the brain and the heart. The mechanism behind this is yet not known.
The study hypothesis is that during hypoglycaemia GLP-1 will stimulate glucose-uptake in the brain and heart independent of insulin and thereby exert protective effects in the brain.
Detailed Description
Type 2 diabetes mellitus, T2D is a disease characterized by an immense growing prevalence world wide. T2D is associated with a three-fold increase in cardiovascular complications (myocardial infarction and stroke) leading to significantly higher morbidity and mortality in this group of patients. The prospective British Diabetes Study (UKPDS) showed that neither diet alone nor the pharmaceutical treatment utilized (Sulphonylurea, Metformin, Insulin) were able to reduce these macrovascular complications. GLP-1 (glucagon-like-peptide-1)is an incretin with convincing effects on glycaemia in type 2 diabetic patients with little or no risk of hypoglycaemia. New research in animal models has shown a potential protective effect in the brain and heart in association with ischaemic damage. The mechanism behind this protective effect is not known. During hypoglycaemia the brain lacks glucose which is the main fuel for sufficient brain function. The brain will compensate by increasing glucose uptake across the blood brain barrier and similarly in the heart.
The effect of native GLP-1 on glucose uptake in the brain and heart will by visualized by fluoro-deoxy-glucose FDG-PET-scan during hypoglycaemia in healthy men. At the same time a pancreatic/pituitary clamp will be performed. The hypothesis is that GLP-1 directly will stimulate glucose uptake independent of the pancreatic hormones and through this mechanism exert neuro- and cardioprotective actions.
Comparisons: FDG-uptake in the brain and heart with GLP-1 infusion compared to placebo.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Stroke, Myocardial Infarction
Keywords
GLP-1, glucose metabolism, Type 2 diabetes, brain, PET
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Active Comparator
Arm Title
P
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
glucagon-like-peptide-1
Intervention Description
intravenous infusion of 1.2pmol/kg/min for 7 hours
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
intravenous infusion of 1.2pmol/kg/min
Primary Outcome Measure Information:
Title
The acute effect of GLP-1 on glucose uptake in the brain
Time Frame
1 hour
Title
The acute effect of GLP-1 on glucose uptake in the heart
Time Frame
1 hour
Secondary Outcome Measure Information:
Title
The acute effect of GLP-1 on glucose metabolic rate in the brain
Time Frame
1 hour
Title
The acute effect of GLP-1 on intracerebral glucose concentration
Time Frame
1 hour
Title
The acute effect of GLP-1 on lumped constant in the brain
Time Frame
1 hour
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy men
Age 20-50 years
Caucasian
BMI 20-30 kg/m2
Exclusion Criteria:
Diabetes in subject and 1.degree relatives
Any disease of clinical relevance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ole E Schmitz, MD, DSc
Organizational Affiliation
Department of pharmacology, Aarhus university
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of pharmacology, Aarhus university
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
24400077
Citation
Gejl M, Lerche S, Mengel A, Moller N, Bibby BM, Smidt K, Brock B, Sondergaard H, Botker HE, Gjedde A, Holst JJ, Hansen SB, Rungby J. Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia. PLoS One. 2014 Jan 6;9(1):e83758. doi: 10.1371/journal.pone.0083758. eCollection 2014.
Results Reference
derived
Learn more about this trial
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
We'll reach out to this number within 24 hrs